Osteoporosis: Diagnosis, Prevention & Evidence-Based Treatment
When bone density drops below the fracture threshold — causes, testing, and what actually works
Osteoporosis affects 10 million Americans and causes 2 million fractures annually. It is defined by a DEXA T-score below -2.5 and represents significant skeletal fragility. Early diagnosis and treatment can reduce fracture risk by 40-70%.
Osteoporosis is a skeletal disorder characterized by reduced bone mass and microarchitectural deterioration, leading to increased bone fragility and fracture susceptibility. It is diagnosed when a DEXA scan reveals a T-score of -2.5 or below at the lumbar spine, femoral neck, or total hip — or when a fragility fracture occurs regardless of T-score.
The clinical significance of osteoporosis lies in its fractures. Hip fractures carry a 20-30% one-year mortality rate in adults over 65. Vertebral compression fractures cause chronic pain, height loss, and kyphosis. Wrist fractures, often the first osteoporotic fracture, are a warning signal for future hip and spine fractures.
Despite effective treatments that reduce fracture risk by 40-70%, osteoporosis remains dramatically undertreated. Only 20-25% of women who sustain an osteoporotic fracture receive appropriate evaluation or treatment afterward.
Diagnosis and Risk Assessment
DEXA scan: Measures bone mineral density at the spine, hip, and sometimes forearm. T-score below -2.5 at any site confirms osteoporosis.
FRAX score: The WHO Fracture Risk Assessment Tool calculates 10-year probability of major osteoporotic fracture and hip fracture using clinical risk factors. Treatment is generally recommended when 10-year hip fracture risk exceeds 3% or major osteoporotic fracture risk exceeds 20%.
Secondary causes to evaluate: Vitamin D deficiency, hyperparathyroidism, hyperthyroidism, celiac disease, multiple myeloma, Cushing's syndrome, hypogonadism, and medication-induced bone loss (corticosteroids, aromatase inhibitors, anticonvulsants).
Treatment Options
First-line pharmacological therapy:
- Bisphosphonates (alendronate, risedronate, zoledronic acid): Reduce fracture risk by 40-50%. Work by inhibiting osteoclast-mediated bone resorption. Oral (weekly) or IV (yearly). Treatment duration: typically 5 years oral, 3 years IV, then reassess.
- Denosumab (Prolia): Monoclonal antibody targeting RANKL. Reduces hip fracture risk by 40%, vertebral by 68%. Given as subcutaneous injection every 6 months. Discontinuation causes rapid bone loss — transition plan required.
Anabolic agents (bone-building):
- Romosozumab (Evenity): Anti-sclerostin antibody that both builds bone and reduces resorption. Increases spine BMD by 13% and hip by 7% over 12 months. Reserved for very high fracture risk. 12-month treatment followed by antiresorptive therapy.
- Teriparatide (Forteo): PTH analog that stimulates osteoblasts. Increases spine BMD by 9-13% over 18-24 months. Maximum 2-year treatment course.
Need help with this next step?
We can match you with a vetted specialist who understands this area and can help you decide what to do next.
Book An Appointment With A Specialist →Lifestyle Interventions
- Exercise: Resistance training and weight-bearing impact exercise remain essential even with pharmacological treatment. Fall prevention (balance training, tai chi) reduces fracture risk by preventing falls, which is equally important as improving bone density.
- Nutrition: Calcium 1,200 mg/day, vitamin D to maintain 25(OH)D above 40 ng/mL, protein 1.0-1.2 g/kg/day. Vitamin K2 (MK-7, 100-200 mcg/day) may improve calcium deposition into bone rather than soft tissues.
- Fall prevention: Home safety assessment (rugs, lighting, grab bars), vision correction, medication review (sedatives, antihypertensives that cause dizziness), and balance exercises reduce fall risk by 30-40%.
Practical guides: DEXA scan and diagnosis, T-score and Z-score, bone-building exercise, calcium-rich foods, earlier-stage osteopenia, and menopause-related bone loss.
Frequently Asked Questions
Can osteoporosis be reversed?
Osteoporosis can be significantly improved with modern treatments. Anabolic agents like romosozumab can increase spine bone density by 13% in 12 months, and teriparatide by 9-13% over 2 years. Bisphosphonates and denosumab prevent further loss and modestly increase density. While complete reversal to normal T-scores is uncommon, reducing fracture risk by 40-70% with treatment is well established.
What are the 3 worst bone density drugs?
This question typically refers to concerns about bisphosphonate side effects. The rare but serious risks include: (1) atypical femur fractures (risk: ~1 in 10,000 per year, mainly with use beyond 5 years), (2) osteonecrosis of the jaw (risk: ~1 in 10,000-100,000 for oral bisphosphonates, higher with IV formulations in cancer patients), and (3) esophageal irritation with oral bisphosphonates. However, for most patients the fracture-prevention benefit far outweighs these risks. Drug holidays after 5 years of oral or 3 years of IV bisphosphonates mitigate long-term risks.
Can osteoporosis be reversed to osteopenia?
Yes, this is achievable with treatment. Anabolic agents (romosozumab, teriparatide) can increase bone density enough to shift T-scores from the osteoporosis range into osteopenia. Even antiresorptive treatments (bisphosphonates, denosumab) can achieve this, particularly at the lumbar spine. The goal of treatment is primarily fracture prevention, but T-score improvement is a measurable outcome.
How to prevent osteoporosis after menopause?
Prevention starts during the accelerated bone loss phase (first 5-7 years postmenopause): (1) progressive resistance training 2-3x/week with impact exercises, (2) calcium 1,200 mg/day from food + supplements, (3) vitamin D 1,000-4,000 IU/day to maintain levels above 40 ng/mL, (4) adequate protein, (5) consider hormone therapy if appropriate (reduces fracture risk 30-40%), and (6) baseline DEXA scan within 2 years of menopause if risk factors are present.
Check Where You Stand
Take our free health assessment to understand your metabolic, hormonal, and recovery risk factors — and get personalized recommendations.
Take the Free Assessment →Free · Takes 5 minutes · Instant results
Continue Reading
← Back to Hormone Optimization
-
Menopause, fatigue, weight gain, and metabolic health
Menopause symptoms, body composition, testing, and treatment paths.
-
Perimenopause symptoms, fatigue, and early hormone changes
Early-transition fatigue, weight gain, sleep disruption, and symptom triage.
-
Low testosterone in men: symptoms, causes, and treatment
Symptoms, causes, and treatment options for low T in men.
-
Hormone imbalance: symptoms, causes, and how to fix it
How hormonal imbalances present differently in men and women.
-
Thyroid symptoms: hypothyroidism vs hyperthyroidism and what your labs mean
Hypothyroidism vs hyperthyroidism — symptoms and what labs reveal.
-
High cortisol symptoms: signs your stress hormones are too high
Chronic stress signs: weight gain, insomnia, anxiety, impaired recovery.
-
Perimenopause symptoms: the complete guide
The complete symptom list — hot flashes affect ~80% of women.
-
Perimenopause fatigue: causes and energy solutions
Why perimenopause causes fatigue and what to do about it.
-
Brain fog: hormonal causes and how to clear it
Hormonal causes of cognitive sluggishness — thyroid, cortisol, estrogen.
-
What causes low testosterone? Root causes explained
Root causes: age, obesity, sleep, medications, chronic illness.